Literature DB >> 27748844

Differential glycolytic profile and Warburg effect in papillary thyroid carcinoma cell lines.

Raquel Guimarães Coelho1, Juliana de Menezes Cazarin1, João Paulo Albuquerque Cavalcanti de Albuquerque1, Bruno Moulin de Andrade1, Denise P Carvalho1.   

Abstract

Acceleration of glycolysis is a characteristic of neoplasia. Previous studies have shown that a metabolic shift occurs in many tumors and correlates with a negative prognosis. The present study aimed to investigate the glycolytic profile of thyroid carcinoma cell lines. We investigated glycolytic and oxidative parameters of two thyroid carcinoma papillary cell lines (BCPAP and TPC1) and the non-tumor cell line NTHY-ori. All carcinoma cell lines showed higher rates of glycolysis efficiency, when compared to NTHY-ori, as assessed by a higher rate of glucose consumption and lactate production. The BCPAP cell line presented higher rates of growth, as well as elevated intracellular ATP levels, compared to the TPC1 and NTHY-ori cells. We found that glycolysis and activities of pentose phosphate pathway (PPP) regulatory enzymes were significantly different among the carcinoma cell lines, particularly in the mitochondrial hexokinase (HK) activity which was higher in the BCPAP cells than that in the TPC1 cell line which showed a balanced distribution of HK activity between cytoplasmic and mitochondrial subcellular localizations. However, TPC1 had higher levels of glucose‑6-phosphate dehydrogenase activity, suggesting that the PPP is elevated in this cell type. Using high resolution respirometry, we observed that the Warburg effect was present in the BCPAP and TPC1 cells, characterized by low oxygen consumption and high reactive oxygen species production. Overall, these results indicate that both thyroid papillary carcinoma cell lines showed a glycolytic profile. Of note, BCPAP cells presented some relevant differences in cell metabolism compared to TPC1 cells, mainly related to higher mitochondrial-associated HK activity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27748844     DOI: 10.3892/or.2016.5142

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation.

Authors:  Raziyeh Abooshahab; Morteza Gholami; Maryam Sanoie; Fereidoun Azizi; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-04-01       Impact factor: 3.633

Review 2.  Metabolic Reprogramming in Thyroid Carcinoma.

Authors:  Raquel Guimaraes Coelho; Rodrigo S Fortunato; Denise P Carvalho
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

3.  Metabolomic Alterations in Thyrospheres and Adherent Parental Cells in Papillary Thyroid Carcinoma Cell Lines: A Pilot Study.

Authors:  Paola Caria; Laura Tronci; Tinuccia Dettori; Federica Murgia; Maria Laura Santoru; Julian L Griffin; Roberta Vanni; Luigi Atzori
Journal:  Int J Mol Sci       Date:  2018-09-27       Impact factor: 5.923

Review 4.  Metabolic reprogramming and its clinical application in thyroid cancer.

Authors:  Shi-Shuai Wen; Ting-Ting Zhang; Di-Xin Xue; Wei-Li Wu; Yu-Long Wang; Yu Wang; Qing-Hai Ji; Yong-Xue Zhu; Ning Qu; Rong-Liang Shi
Journal:  Oncol Lett       Date:  2019-06-18       Impact factor: 2.967

5.  Oxidative Stress-Induced Sirtuin1 Downregulation Correlates to HIF-1α, GLUT-1, and VEGF-A Upregulation in Th1 Autoimmune Hashimoto's Thyroiditis.

Authors:  Michaël Hepp; Alexis Werion; Axel De Greef; Christine de Ville de Goyet; Marc de Bournonville; Catherine Behets; Benoit Lengelé; Chantal Daumerie; Michel Mourad; Marian Ludgate; Marie-Christine Many; Virginie Joris; Julie Craps
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

6.  Beta-elemene inhibits differentiated thyroid carcinoma metastasis by reducing cellular proliferation, metabolism and invasion ability.

Authors:  Lei Zhao; Jian Wei; Shiqi Wang; Tingting Lang; Xiaoguang Shi; Zhongyan Shan; Weiping Teng
Journal:  Ann Transl Med       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.